The expression of 5␣-reductase types 1 and 2 was examined in human breast carcinoma using immunohistochemistry and RT-PCR. Immunoreactivity for 5␣-reductase isozymes was also correlated with various clinicopathological parameters to examine possible local regulatory mechanisms of sex steroids, including progesterone and androgens, in human breast carcinoma tissues. Immunoreactivity for 5␣-reductase type 1 was detected in the cytoplasm and possibly in the nuclear membrane of tumor cells in 35 of 60 invasive ductal carcinomas (58%), and type 2 signal was detected in 9 of these 60 cases (15%). The results from RT-PCR (n ϭ 8) were consistent with those from immunohistochemistry. A significant positive correlation was detected between 5␣-reductase type 1 immunoreactivity and androgen and progesterone receptor A or B labeling indexes, and immunoreactivities of 5␣-reductase type 2, 17␤-hydroxysteroid dehydrogenase type 5, or 3␤-hydroxysteroid dehydrogenase, which recognizes both types I and II. An inverse correlation was detected between 5␣-reductase type 1 immunoreactivity and tumor size, histological grade, or Ki-67 labeling index. 5␣-Reductase type 2 immunoreactivity was significantly correlated with 17␤-hydroxysteroid dehydrogenase type 5 immunoreactivity, but not with other parameters. This study suggests that 5␣-reductase type 1 is mainly expressed in human breast carcinoma, which may play an important role in the in situ production and actions of the potent androgen, 5␣-dihydrotestosterone, including inhibition of cancer cell proliferation, in hormonedependent human breast carcinoma. (J Clin Endocrinol
B
REAST CARCINOMA is one of the most common malignancies in women world-wide. It is well known that human breast tissue is a target for sex steroids, which play important roles in the development of hormone-dependent breast carcinomas (1, 2) . Among the various sex steroids, estrogens contribute immensely to the growth of breast carcinoma through binding with the estrogen receptor (ER) (1, 2) . In contrast, various previous in vitro studies have demonstrated that progesterone and androgens inhibit the proliferation of breast carcinoma cells via progesterone (PR) and androgen (AR) receptors, respectively (3) (4) (5) (6) . PR and AR have been shown to be expressed in the majority of breast carcinoma tissues (7, 8) and are considered to be important mediators of hormonal additive therapy, including progesterone and androgen, in human breast tumors (9, 10) . However, the detailed mechanism of progesterone and androgen actions in human breast carcinoma tissues is largely unknown compared with that of estrogen actions.
5␣-Reductases catalyze the conversion of testosterone to the bioactive and potent androgen, 5␣-dihydrotestosterone (DHT), and metabolize progesterone to 5␣-dihydroprogesterone (5␣DHP) (11) . Therefore, 5␣-reductase expression is an important regulator of the local actions of androgens and progesterone. Two isoforms of 5␣-reductase have been cloned and characterized in mammals. The type 1 5␣-reductase is located on the distal short arm of chromosome 5 (11) and is mainly expressed in the liver and skin (12) . Type 2 5␣-reductase is located in band p23 of chromosome 2 (13) and is expressed in the liver, prostate, seminal vesicle, and epididymis (12) . Recently, several selective inhibitors of 5␣-reductase isozymes (e.g. MK-386 for type 1 and finasteride for type 2) have been developed and used in the treatment of androgen-dependent disorders, including skin and prostate pathologies (14) . Therefore, it is very important to examine the expression of 5␣-reductase isozymes to obtain a better understanding of the role of 5␣-reductase and its regulation in various human tissues and their disorders. Enzymatic activity for 5␣-reductase has been demonstrated in both breast cancer cell lines (15) and breast cancer tissues themselves (16) . 5␣-Reductase isozymes are considered to play important roles as local regulators of sex steroid actions in human breast carcinoma, similar to P450 aromatase, which is regulator of estrogen actions. However, the expression of 5␣-reductase isozymes has not been examined in breast carcinoma, and its biological significance remains unknown. Therefore, in this study we examined the expression of 5␣-reductase type 1 and type 2 in human breast carcinoma tissues using immunohistochemistry and RT-PCR. In addition, we statistically correlated the immunoreactivity of 5␣-reductase isozymes with various clinicopathological parameters in 60 cases of human breast carcinoma to study the
Immunohistochemistry
Immunohistochemical analysis was performed employing the streptavidin-biotin amplification method using a Histofine Kit (Nichirei, Tokyo, Japan) and has been previously described in detail (26) . For immunostaining of AR, PR-A, PR-B, ER, Ki-67, and HER-2/neu, the slides were heated in an autoclave at 120 C for 5 min in citric acid buffer (2 mmol/L citric acid and 9 mmol/L trisodium citrate dehydrate, pH 6.0) after deparaffinization for antigen retrieval. The dilutions of primary antibodies used in our study were as follows: 5␣-reductase type 1, 1:1000; 5␣-reductase type 2, 1:1000; AR, 1:100; PR-A, 1:150; PR-B, 1:150; ER, 1:2; 17␤HSD5, 1:1000; 3␤HSD, 1:1000; Ki-67, 1:50; and HER-2/neu, 1:200. The antigen-antibody complex was visualized with 3,3Ј-diaminobenzidine solution [1 mmol/L 3,3Ј-diaminobenzidine, 50 mmol/L Tris-HCl buffer (pH 7.6), and 0.006% H 2 O 2 ] and counterstained with hematoxylin. Tissue sections of liver and prostate were used as positive controls for 5␣-reductase type 1 and type 2, respectively (12) , and nonneoplastic breast tissue was used as a positive control for 17␤HSD type 5 (19) . As a negative control, normal rabbit or mouse IgG was used instead of the primary antibodies, and no specific immunoreactivity was detected in these sections.
RT-PCR
RT-PCR analysis was performed on eight specimens of invasive ductal carcinoma. Total ribonucleic acid (RNA) was extracted from frozen breast carcinoma tissue samples using an RNeasy Total RNA isolation kit (QIAGEN, Hilden, Germany). RNA concentrations were determined spectrophotometrically. Total RNA (5 g) was denatured at 70 C for 10 min and was reverse transcribed in the presence of 25 ng/l oligo(deoxythymidine) [12] [13] [14] [15] [16] [17] [18] primer (Life Technologies, Inc., Tokyo, Japan), 2.5 mmol/L MgCl 2 , 0.5 mmol/L deoxy-NTPs, 10 mmol/L dithiothreitol, and 10 U ribonuclease H Ϫ reverse transcriptase (SuperScript II RT, Life Technologies, Inc., Tokyo, Japan) for 20 min at 23 C, 60 min at 42 C, and 15 min at 70 C. Subsequently, 1 L of the resulting complementary DNA (cDNA) was used as a template for PCR. The primer sequences used in this study (27) (28) (29) (30) are listed in Table 1 ). An initial denaturing step of 95 C for 2 min was followed by 40 cycles (AR and 5␣-reductase type 1 and type 2) and 30 cycles (␤-actin), respectively, of 95 C for 1 min; 1-min annealing at 50 C (5␣-reductase type 1), 60 C (5␣-reductase type 2), 56 C (AR), and 58 C (␤-actin); and a final extension for 2 min at 72 C. All PCR cycling was performed on a PTC-200 Peltier Thermal Cycler DNA Engine (MJ Research, Inc., Watertown, MA). After PCR, the products were resolved on a 2% agarose ethidium bromide gel. Images were captured with Polaroid (Hertfordshire, UK) film under UV transillumination. In initial experiments, after amplification PCR products were purified and subjected to direct sequencing (ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit and ABI Prism 310 Genetic Analyzer, Perkin-Elmer Corp. PE Applied Biosystems, Foster City, CA) to verify amplification of the correct sequences. As a positive control, frozen tissues of liver were used for 5␣-reductase type 1 and AR, and those of prostate were used for 5␣-reductase type 2. Negative control experiments lacked the cDNA substrate to check for the possibility of exogenous contaminant DNA. No amplified products were observed under these conditions.
Scoring of immunoreactivity
For statistical analyses of 5␣-reductase type 1 and type 2, 17␤HSD type 5, 3␤HSD, and HER-2/neu immunoreactivity, the carcinomas were classified into two groups (ϩ, positive carcinoma cells; and Ϫ, no im- a Oligonucleotide primers for 5␣-reductase type 2 were designed using the previously published cDNA sequence for human 5␣-reductase type 2 by Andersson et al. (28) . munoreactivity) by three of the authors (T.S., T.M., and N.A.) independently. Cases with discordant results among the observers were reevaluated. Scoring of AR, PR-A, PR-B, ER, and Ki-67 in carcinoma cells was performed on high power fields (ϫ400) using a standard light microscope. In each case, more than 500 carcinoma cells were counted independently by these same three authors, and the percentage of immunoreactivity, i.e. labeling index (LI), was determined. In the present study interobserver differences were less than 5%, and the mean of the three values was obtained.
Statistical analysis
Values for patient age, tumor size, and LIs for AR, PR-A, PR-B, ER, and Ki-67 were presented as the mean Ϯ 95% confidence interval (95% CI), and associations between the immunoreactivity of 5␣-reductases and these parameters were evaluated using a Bonferroni test. Statistical differences between immunoreactivity for 5␣-reductases and menopausal status, stage, lymph node status, histological grade, and immunoreactivity for 17␤HSD5, 3␤HSD, and HER-2/neu were evaluated in a cross-table using the 2 test. P Ͻ 0.05 was considered significant. Overall and disease-free survival analyses were calculated according to the Kaplan-Meier test. The statistical significance of differences in the survival analyses was calculated using the log-rank test.
Results

Immunohistochemistry
Immunoreactivity for 5␣-reductase type 1 and type 2 was detected in the cytoplasm and possibly in the nuclear membrane of carcinoma cells (Fig. 1, A and B) . The number of positive cases and percentages were 35 of 60 cases (58.3%) for 5␣-reductase type 1, and 9 of 60 cases (15.0%) for 5␣-reductase type 2, respectively. Immunoreactivity for 5␣-reductase type 1 and type 2 was focally detected in morphologically normal glandular epithelia adjacent to the carcinoma. To examine the possible effects of long-term storage of the samples on immunoreactivity of 5␣-reductases, we performed immunohistochemistry for 5␣-reductase types 1 and 2 in 12 invasive ductal carcinomas collected within 1 yr. Immunoreactivity for 5␣-reductase type 1 and type 2 was detected in 8 of 12 (66.7%) and 3 of 12 (25.0%), respectively.
Immunoreactivity for AR (Fig. 1C) , PR-A, PR-B, and ER was detected in the nuclei of carcinoma cells, and the number of positive cases and percentages were 49 of 60 (81.7%), 33 of 60 (55%), 38 of 60 (63.3%), and 51 of 60 (85.0%), respectively. Immunoreactivity for 17␤HSD type 5 was detected in cytoplasms of carcinoma cells (Fig. 1D ) in 37 of 60 cases (61.7%) examined. Immunoreactivity for 17␤HSD5 was also detected in the cytoplasms of morphologically normal glandular epithelial cells and some stromal cells adjacent to the carcinoma, as reported previously (19) . 3␤HSD immunoreactivity was detected in the cytoplasms of carcinoma cells in 32 cases (53.3%; Fig. 2 ). Ki-67 immunoreactivity was detected in the nuclei of carcinoma cells as well as some stromal cells in all cases examined. HER-2/neu immunoreactivity was detected in membranes of carcinoma cells in 27 of 60 cases (45%) in this study.
RT-PCR
As shown in Fig. 3 , messenger RNA (mRNA) expression for 5␣-reductase type 1 and type 2 and AR was detected as a specific single band (308 bp for 5␣-reductase type 1, 315 bp for 5␣-reductase type 2, and 420 bp for AR) in eight of three (100%), three of eight (37.5%), and eight of eight (100%) cases, respectively. The results of RT-PCR analyses in each case were consistent with those of immunohistochemistry.
Correlation between 5␣-reductases and clinicopathological parameters
The results of correlation between 5␣-reductases and clinicopathological parameters are summarized in Table 2 . As shown in Table 2A , a significant inverse correlation was detected between 5␣-reductase type 1 immunoreactivity and tumor size (P ϭ 0.043) or histological grade of the carcinoma tissue (P ϭ 0.013). There was, however, no significant correlation between 5␣-reductase type 1 immunoreactivity and 
FIG. 3.
RT-PCR analysis for 5␣-reductase type 1 and type 2 and AR in eight invasive ductal carcinomas. mRNA expression for 5␣-reductase type 1 and 2, AR, and ␤-actin were detected as a specific single band (308 bp for 5␣-reductase type 1, 315 bp for 5␣-reductase type 2, 420 bp for AR, and 532 bp for ␤-actin). mRNA expression was detected in eight of eight cases for 5␣-reductase type 1, three (cases 3, 4, and 7) of eight cases for 5␣-reductase type 2, and eight of eight cases for AR. P, Positive controls (liver for 5␣-reductase type 1 and AR, and prostate for 5␣-reductase type 2); Liv, liver; Pro, prostate; N, negative control (no cDNA substrate).
patient age, menopausal status, stage, or lymph node status. 5␣-Reductase type 2 immunoreactivity was not significantly correlated with any clinicopathological parameters examined in this study (Table 2B) .
Correlation between 5␣-reductases and steroid receptors and enzymes
The results of correlation between 5␣-reductase type 1 and immunohistochemical parameters are summarized in Table  3A . There was a strong correlation between 5␣-reductase type 1 immunoreactivity and AR LI (P ϭ 0.0026). A significant positive correlation was also detected between 5␣-reductase type 1 immunoreactivity and 5␣-reductase type 2 immunoreactivity (P ϭ 0.030), PR-A LI (P ϭ 0.039), PR-B LI (P ϭ 0.042), 17␤HSD type 5 immunoreactivity (P ϭ 0.0034), and 3␤HSD immunoreactivity (P ϭ 0.023). There was a significant inverse correlation between 5␣-reductase type 1 immunoreactivity and Ki-67 LI (P ϭ 0.020). The results of correlation between 5␣-reductase type 2 and these parameters above are summarized in Table 3B . 5␣-Reductase type 2 immunoreactivity was significantly correlated with 17␤HSD type 5 immunoreactivity (P ϭ 0.010), but other significant correlations were not detected in this study.
Correlation between 5␣-reductases and prognosis
No significant correlation was detected between 5␣-reductase type 1 or type 2 immunoreactivity and overall or disease-free survival in the 60 invasive ductal carcinomas investigated in this study.
Discussion
In this study immunoreactivity for 5␣-reductase type 1 was detected in carcinoma cells in 35 of 60 human breast carcinomas (58.3%), whereas that of 5␣-reductase type 2 was detected in carcinoma cells in 9 of 60 cases (15.0%) examined. Activity of 5␣-reductase has previously been demonstrated in various human breast carcinoma cell lines (15, 31) , and Wiebe et al. (16) reported that 5␣-reductase activity was 4 -8 times elevated in breast cancer tissues compared with that in nontumorous breast tissues. Results from our present study are consistent with these previous reports and suggest that type 1 5␣-reductase is mainly expressed in carcinoma cells of human breast carcinoma tissues. Immunoreactivity for 5␣-reductase types 1 and 2 was detected in the cytoplasm and possibly in the nuclear membrane in this study. These findings are consistent with previous reports that describe both of these antigens as being integral membrane proteins localized to the endoplasmic reticulum and the contiguous nuclear membrane (11) . However, further investigations, including ultrastructural immunohistochemistry, are required to study the precise subcellular localization of 5␣-reductase type 1 and type 2 in human breast carcinoma cells.
In this study 5␣-reductase type 1 immunoreactivity was significantly correlated with AR LI (P ϭ 0.0026), which suggests that 5␣-reductase type 1 plays an important role in the regulation of local androgenic actions. Previously, Isola (8) reported that 79% of breast carcinomas expressed AR, suggesting that androgenic actions are present in human breast carcinoma tissues. Physiological concentrations of potent androgens such as DHT were very low in normal woman (32) (33) (34) and in breast cancer patients (35) . However, Recchione et al. (36) demonstrated that DHT concentrations were significantly higher (3-fold increase; P ϭ 0.0001) in breast cancer tissues than in plasma and suggested the possible local production of DHT in human breast carcinoma tissues. Recently, 17␤HSD type 5, which specifically catalyzes the reduction of androstenedione to testosterone, was cloned by Dufort et al. (37) . 17␤HSD type 5 is expressed in various peripheral tissues, including the breast (19) , and El-Alfy (38) proposed possible in situ production of DHT from the inactive adrenal precursor dehydroepiandrosterone (DHEA) by 3␤HSD (conversion from DHEA to androstenedione), 17␤HSD type 5 (reduction of androstenedione to testosterone), and 5␣-reductases (metabolism of testosterone to DHT) in various peripheral tissues. Previous studies have reported the presence of 3␤HSD activity in breast carcinoma tissues (39) and that of 17␤HSD activity in breast carcinoma cell lines (31) in addition to 5␣-reductase activity in human breast carcinoma tissues (16) . An immunohistochemical study of 3␤HSD in breast carcinoma cells has been previously reported by Sasano et al. (40) , but that of 17␤HSD type 5 or 5␣-reductases has not been examined. In this study immunoreactivity for 3␤HSD and 17␤HSD type 5 was detected in carcinoma cells in 32 (53.3%) and 37 (61.7%) of 60 invasive ductal carcinomas, respectively, and immunoreactivity for 5␣-reductase type 1 was correlated with that of 3␤HSD (P ϭ 0.023) or 17␤HSD type 5 (P ϭ 0.0034) immunoreactivity. Therefore, the results of our study suggest that DHT is locally produced by 3␤HSD, 17␤HSD type 5, and 5␣-reductase type 1 in carcinoma cells and acts on these cells locally via AR in human breast carcinoma tissues.
There was a significant inverse correlation between 5␣-reductase type 1 immunoreactivity and Ki-67 LI (P ϭ 0.020) or tumor size (P ϭ 0.043) in this study. Monoclonal antibody Ki-67 has been demonstrated to recognize cells in all phases of the cell cycle except the G 0 (resting) phase (41), and Ki-67 LI is well recognized to be a useful factor to evaluate the proliferative activity of various neoplastic tissues, including breast carcinoma (42) . Previous in vitro studies have demonstrated that DHT inhibited the basal and estrogen-induced cell proliferation in human breast cancer cell lines through actions on AR, and this effect occurred at physiological concentrations (4, 6) . Our present findings are in good agreement with these previous in vitro studies mentioned above and suggest that 5␣-reductase type 1 locally induces DHT production and results in a relatively low proliferation rate in human breast carcinoma. 5␣-Reductase type 1 immunoreactivity was also inversely correlated with histological grade (P ϭ 0.013). Therefore, breast carcinomas positive for 5␣-reductase type 1 are considered to be relatively well differentiated and may maintain some hormonal regulatory mechanisms. Administration of androgens has been reported to result in the regression of some cases of breast carcinoma, but also to cause androgenic side-effects (5). Therefore, induction of 5␣-reductase type 1 may be effective, with fewer sideeffects, in the treatment of breast carcinomas as one possible endocrine therapy.
Recent studies have demonstrated that the bioactive estrogen, estradiol, was produced locally in breast carcinoma tissues. P450 aromatase converts androstenedione to estrone and testosterone to estradiol. Enzymatic activity of aromatase has been demonstrated in human breast carcinoma tissues (43) , and aromatase immunolocalization has been reported in stromal cells of breast carcinoma tissues (40) . Immunoreactivity for 17␤HSD type 1, which catalyzes the conversion of estrone to estradiol, has been reported in carcinoma cells in breast carcinoma tissues (44 -46) and has been correlated with ER LI (46) . AR-positive breast carcinomas are frequently positive for ER (8) , and thus, it is reasonable to observe a strong correlation between AR and ER LIs (r ϭ 0.400; P ϭ 0.0015) in this study. Therefore, 17␤HSD type 5 and 5␣-reductases may act to increase DHT production through competition with aromatase of estrogen production in hormone-dependent breast carcinomas (Fig. 4) .
Previous studies have reported that progesterone exerts a direct antiproliferative effect (3, 5) and abolishes the stimulatory effects of estradiol on the growth of breast cancer cells
5␣-REDUCTASE IN HUMAN BREAST CANCER(5). Progesterone actions are mediated via two isoforms of PR, PR-A (81-83 kDa) and PR-B (116 -120 kDa)
. PR is present in approximately 60% of breast carcinoma tissues (7), and the presence of PR is an important indicator of the responsiveness to endocrine agents in human breast carcinoma (10) . Recently, Wiebe et al. (16) demonstrated that progesterone metabolites to 5␣DHP and 3␣-hydroxyprogesterone (3␣-HP) by 5␣-reductase and 3␣-hydroxysteroid oxidoreductase, respectively, and the ratio of 5␣DHP/3␣-HP was nearly 30-fold higher in tumorous than in nontumorous breast tissues using enzymatic assay. They also reported that 5␣DHP stimulated, whereas 3␣-HP inhibited, the proliferation and detachment of breast cell lines in vitro. These previous findings above suggest that 5␣-reductase may decrease the biological actions of progesterone, including the antiproliferative effect. However, in this study, 5␣-reductase type 1 immunoreactivity was correlated with PR-A and PR-B LIs (P ϭ 0.039 and P ϭ 0.042, respectively), and inversely correlated with Ki-67 LI (P ϭ 0.020) or tumor size (P ϭ 0.043). Therefore, evidence of regulation of progesterone action by 5␣-reductases could not be verified. This may partly be due to the concentration of progesterone being lower than that of DHT, which may be locally produced in human breast carcinoma tissues. However, studies are required to confirm these speculations.
In summary, we demonstrated that 5␣-reductase type 1 is mainly expressed in human breast carcinomas by immunohistochemistry and RT-PCR. Immunoreactivity for 5␣-reductase type 1 was significantly correlated with AR, PR-A or PR-B LI, and 5␣-reductase type 2, 17␤HSD type 5, or 3␤HSD immunoreactivity and was inversely correlated with tumor size, histological grade, or Ki-67 LI. Our present data suggest that 5␣-reductase type 1 plays an important role in the regulation of in situ DHT production and actions, including the inhibition of cancer cell proliferation, in hormone-dependent breast carcinomas.
FIG. 4.
Flow chart illustrating the possible cascade of local production of androgens and estrogens in human breast carcinoma. DHT is locally produced from the inactive adrenal precursor DHEA by 3␤HSD (conversion from DHEA to androstenedione), 17␤HSD type 5 (reduction of androstenedione to testosterone), and 5␣-reductases (metabolism of testosterone to DHT) and acts on the carcinoma cells through the AR. On the other hand, estradiol is locally produced by aromatase (conversion from androstenedione to estrone and from testosterone to estradiol) and 17␤HSD type 1 (conversion of estrone to estradiol) and binds to ER in the carcinoma cells.
